SCHEMBL4133816

SCHEMBL4133816

O=C(O)CCCCCC(C(=O)O)c1ccc(NC2=NC(=O)/C(=C\c3cc4ccccc4cc3OCc3ccc(-c4ccccc4)cc3)S2)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 4/20 0.45
POLB P06746 3/20 0.36
PTPN1 P18031 1/20 0.36
LTB4R Q15722 2/20 0.33
PPARG P37231 1/20 0.33
CISD1 Q9NZ45 1/20 0.33
PSMD14 O00487 1/20 0.33
PLEC Q15149 1/20 0.33
FFAR1 O14842 2/20 0.32
ALOX5 P09917 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HDAC1 Q13547 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4133819 1.00 PTP4A3 (0.45) PTP4A3POLBPTPN1LTB4RPPARG
SCHEMBL4139394 0.89 PPARG (0.36) PTP4A3POLBPPARGALOX5TDP1
SCHEMBL4139389 0.89 PPARG (0.36) PTP4A3POLBPPARGALOX5TDP1
SCHEMBL4122595 0.84 PTP4A3 (0.46) PTP4A3POLBPTPN1CISD1TDP1
SCHEMBL4122600 0.84 PTP4A3 (0.46) PTP4A3POLBPTPN1CISD1TDP1
SCHEMBL4137638 0.82 PTP4A3 (0.51) PTP4A3POLBPTPN1PPARGCISD1
SCHEMBL4137639 0.82 PTP4A3 (0.51) PTP4A3POLBPTPN1PPARGCISD1
SCHEMBL4125736 0.80 PTP4A3 (0.50) PTP4A3POLBPTPN1CISD1TDP1
SCHEMBL4125733 0.80 PTP4A3 (0.50) PTP4A3POLBPTPN1CISD1TDP1
SCHEMBL4129152 0.79 PTP4A3 (0.46) PTP4A3POLBPTPN1CISD1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTP4A3 26/4885POLB 3123/4885PTPN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.